文献速递白血病造血干细胞移植与细胞治疗

CD19 CAR-T细胞是B系急性淋巴细胞白血病移植后复发的有效治疗:德国真实世界数据

CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany.
PubMed 文献 · Blood Adv · 2023-01-01

这项德国回顾性研究纳入81例前体B细胞急性淋巴细胞白血病(pB-ALL)患者,评估替沙仑赛(Tisa-cel)真实世界疗效。输注后28天71例(87.7%)达完全缓解,2年无事件生存率、无复发生存率和总生存率分别为45.3%、51.7%和53.2%。移植后6个月内复发者无事件生存率仅18.4%,6个月后复发者为55.5%。

要点

  • 输注后28天87.7%(71/81)达完全缓解,9.9%(8/81)未缓解。
  • 2年无事件生存率45.3%、无复发生存率51.7%、总生存率53.2%。
  • 移植后6个月内复发者无事件生存率18.4%,6个月后复发者55.5%。

核心结论

  • 替沙仑赛(Tisa-cel)在儿童、青少年和年轻成人pB-ALL真实世界中,多数患者为异基因造血干细胞移植(allo-HSCT)后复发,45.3%经单次输注获得挽救。
  • allo-HSCT后6个月以后复发者无事件生存率远优于6个月内复发者,这一新发现可能有助于临床决策并促使研究其机制。

研究设计与样本

  • 回顾性研究,邀请德国所有CAR-T细胞中心参与。
  • 纳入81例前体B细胞急性淋巴细胞白血病(pB-ALL)患者。
  • 无既往allo-HSCT者16例,有既往allo-HSCT者65例。

主要发现

  • 输注后28天71例(87.7%)达完全缓解,8例(9.9%)未缓解。
  • 2年无事件生存率(pEFS)45.3%、无复发性存率(pRFS)51.7%、总生存率(pOS)53.2%。
  • 无既往allo-HSCT者(n=16)pEFS为55.0%,有既往allo-HSCT者(n=65)为43.4%,两组无差异。
  • allo-HSCT后6个月内复发者pEFS为18.4%(pOS=16.0%),6个月后复发者pEFS为55.5%(pOS=74.8%)。

关键数值与推荐

  • 输注后28天完全缓解率87.7%(71/81),未缓解率9.9%(8/81)。
  • 2年pEFS 45.3%、pRFS 51.7%、pOS 53.2%。
  • 无既往allo-HSCT者pEFS 55.0% vs 有既往allo-HSCT者43.4%,无差异。
  • allo-HSCT后6个月内复发者pEFS 18.4%(pOS=16.0%)vs 6个月后复发者55.5%(pOS=74.8%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with precursor B-cell acute lymphoblastic leukemia (pB-ALL) who have relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT), have relapsed more than once, or are resistant upfront have a dismal prognosis. CD19-targeted chimeric antigen receptor (CAR) T cells have evolved as potent immune therapies. Tisagenlecleucel (Tisa-cel) is a commercially available autologous CD19-directed CAR T-cell product. We performed a retrospective study inviting all CAR T-cell centers in Germany to participate. Eighty-one patients with pB-ALL were included. Twenty-eight days after CAR T-cell infusion, 71 patients (87.7%) were in complete response, and 8 (9.9%) were in nonremission. At 2 years, the probabilities of event-free survival (pEFS), relapse-free survival (pRFS), and overall survival (pOS) were 45.3%, 51.7%, and 53.2%, respectively. pEFS was not different in patients without (n = 16, 55.0%) vs with prior allo-HSCT (n = 65, 43.4%). In patients treated after allo-HSCT, the time to relapse after allo-HSCT was a strong predictor of outcome. Patients relapsing within 6 months of allo-HSCT had a disappointing pEFS of 18.4% (pOS = 16.0%); the pEFS for those relapsing later was 55.5% (pOS = 74.8%). Our study provides real-world experience in pediatric, adolescent, and young adult patients with ALL treated with Tisa-cel, where most patients were treated after having relapsed after allo-HSCT. A total of 45.3% were rescued with a single dose of Tisa-cel. Our novel finding that patients with ALL after allo-HSCT had by far a better pEFS if relapse occurred beyond 6 months might be helpful in clinical decision-making and motivates studies to uncover the reasons.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bader P, Rossig C, Hutter M, et al. CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: real-world data from Germany. Blood Adv. 2023. PMID: 36607834. doi:10.1182/bloodadvances.2022008981

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。